Inflazyme Initiates Multi-Dose Phase I Clinical Trial with GH9001.Business Editors VANCOUVER, British Columbia--(BUSINESS WIRE)--Nov. 3, 2003 Inflazyme Pharmaceuticals Ltd. (TSX TSX Toronto Stock Exchange (TSE before April, 2002) TSX Transfer from Stack Pointer to Index TSX True Space Extension : IZP IZP Inorganic Zinc Primer IZP Inter-Zone Path ) today announced that it has commenced Phase Ib human clinical trials in the United Kingdom with GH9001, a novel antithrombotic compound being developed for the prevention of blood clotting blood clotting, process by which the blood coagulates to form solid masses, or clots. In minor injuries, small oval bodies called platelets, or thrombocytes, tend to collect and form plugs in blood vessel openings. in vascular diseases vascular diseases, n.pl diseases of the peripheral circulatory system. . This Phase Ib study is a double-blind, placebo controlled, multi-dose study in healthy subjects, who will receive GH9001 subcutaneously, twice daily for 4 days, and a single dose on the 5th day. The study is designed to assess the safety and tolerability of the compound together with surrogate markers of activity through effects on measures of blood clotting. GH9001 is a novel proprietary formulation of a medium molecular weight heparin and a highly sulfated, low molecular weight dermatan sulfate. Each component utilizes a different endogenous antithrombotic mechanism, utilizing antithrombin III and heparin cofactor II Heparin cofactor II is a coagulation factor that inhibits IIa, and is a cofactor for heparin and dermatan sulfate ("minor antithrombin"). External links
Subject to satisfactory results from the phase I studies, a phase II study is expected to be initiated in 2004 under a US IND. Ian McBeath, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Inflazyme, said "GH9001 came to us as part of our GlycoDesign acquisition. We are pleased to be advancing the clinical development of this compound to create value from our extended clinical pipeline." Inflazyme is a Vancouver based biopharmaceutical company focused on developing new therapies for the treatment of inflammation, thrombosis and other related diseases. Further information on the Company may be obtained from its website at http://www.inflazyme.com. Statements in this news release other than historical information are forward-looking statements subject to risks and uncertainties. Actual results could differ materially depending on factors such as the availability of resources, the timing and effects of regulatory actions, the strength of competition, the outcome of litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. and the effectiveness of patent protection. Additional information regarding risks and uncertainties is set forth in the current Annual Information Form for Inflazyme on file with the Canadian Securities Commissions. The Toronto Stock Exchange Toronto Stock Exchange (TSE) Canada's largest stock exchange, trading approximately 1,200 company stocks and 33 options. has not reviewed and does not accept responsibility for the adequacy or accuracy of this information. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion